<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2255">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355429</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200410</org_study_id>
    <nct_id>NCT04355429</nct_id>
  </id_info>
  <brief_title>Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)</brief_title>
  <acronym>CAPTOCOVID</acronym>
  <official_title>Efficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Captopril being an effective drug available in liquid preparation, administration by
      nebulization could be of interest for maximizing lung action and minimizing systemic side
      effects. Such a treatment might be used for &quot;Covid-19&quot; patients with pneumonia in order to
      avoid ARDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus Disease 2019 (COVID-19) is due to SARS-CoV-2 infection. The main cause of death
      is refractory acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 pneumonia.
      The SARS-CoV-2 may have specific virulence factors to achieve mortality rates around 3%. As
      the SARS-CoV, virus responsible of the Severe Acute Respiratory Syndrome in 2003 (which
      mortality was around 10%), the SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as the
      receptor binding domain for its spike protein making ACE2 the gateway in the alveolar
      epithelial cells1. Angiotensin-converting enzyme (ACE) and ACE2 are known to be present in
      respiratory epithelium and to have antagonist physiological functions. ACE2 has an
      anti-inflammatory, anti-fibrosing role, anti-oxydant and vasodilatator activity, while ACE
      has the opposite characteristics. These two enzymes have a negative control on each other,
      one inhibiting the other. Demonstrated that SARS-CoV is responsible of a downregulation of
      ACE2 functions by using ACE2 as cell receptor2. While ACE2 is downregulated, ACE activity
      increase leading to more alveolar damage and acute respiratory failure.

      ACE inhibitors are common drugs used to treat hypertension worldwide. Using an ACE inhibitor
      as treatment against SARS-CoV-2 could be counter-intuitive because increasing ACE2 expression
      would open the cellular gate to the virus3,4. However, ACE2 was described as protecting lung
      injury2, leading Recombinant Human ACE2 as a perspective for SARS-CoV-2 treatment.

      A simple way to increase ACE2 in patients with SARS-CoV-2 pneumonia could be an inhalation of
      ACE inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 5, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of captopril nebulization addition to standard of care compared to standard of care.</measure>
    <time_frame>14 Days</time_frame>
    <description>To assess determine the efficacy of captopril nebulization addition to standard of care compared to standard of care in term of 14-day ventilation free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Pneumonia</condition>
  <condition>Coronavirus Infection</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>CAPTOPROL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation administration by nebulization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STANDARS CARE</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>According to surviving covid-Campaign guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>captopril 25mg</intervention_name>
    <description>Drug administration</description>
    <arm_group_label>CAPTOPROL</arm_group_label>
    <other_name>Any</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hospitalization for acute respiratory failure requiring oxygen administration ≥3L/mn

          2. Age &gt; 18 years or older

          3. Presence of pneumonia

          4. PCR SARS-CoV-2 positive in any biological sample in the last 7 days

          5. Patient affiliated to social security regime

          6. Written informed consent provided by the patient or alternatively by next-of-kin, or
             in emergency situations, prior to any protocol-specific procedures

        Exclusion Criteria:

          1. Decision of withholding invasive mechanical ventilation

          2. Shock requiring vasopressor infusion

          3. Co-infection with another respiratory pathogen which could be responsible of pneumonia

          4. Hypersensitivity to captopril, to any other angiotensin converting enzyme inhibitor or
             any of the excipients of the specialty used

          5. History of angio-oedema

          6. History of ACE-inhibitor allergy

          7. Known pregnancy or current lactation: Female subject of childbearing potential should
             have a negative serum pregnancy test prior to receiving the first dose of study
             medication.

          8. Patient who is currently enrolled in other investigational study;

          9. Persons deprived of their liberty by judicial or administrative decision,

         10. Persons under legal protection/safeguard of justice,

         11. Patients under duress psychiatric care,

         12. Persons admitted to a health or social institution

         13. Patient on state medical aid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yacine TANDJAOUI-LAMBIOTTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammed RAHAOUI, PM</last_name>
    <phone>+33 1 48 95 59 77</phone>
    <email>mohammed.rahaoui@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yacine TANDJAOUI-LAMBIOTTE, MD</last_name>
    <email>yacine.tandjaoui-lambiotte@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Victor Dupuy- Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pascale LONGUET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne,</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier BOUCHAUD, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yacine TANDJAOUI-LAMBIOTTE, MD</last_name>
      <email>yacine.tandjaoui-lambiotte@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nunes HILARIO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Compiègne-Noyon</name>
      <address>
        <city>Compiègne</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne-Lise LECAPITAINE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Sud Ile de France</name>
      <address>
        <city>Melun</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvain DIAMANTIS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié- Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre BLEIBTREU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gilles PIALOUX, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours, Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Louis BERNARD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent PLANTIER, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4.</citation>
    <PMID>32129518</PMID>
  </reference>
  <results_reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </results_reference>
  <results_reference>
    <citation>Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005 Sep 16;309(5742):1864-8.</citation>
    <PMID>16166518</PMID>
  </results_reference>
  <results_reference>
    <citation>Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005 Jul 7;436(7047):112-6.</citation>
    <PMID>16001071</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.</citation>
    <PMID>32125455</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Captopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

